Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2025
UK Government, pharma industry fail to agree on medicines payment scheme
28 August 2025 - Negotiations between the UK Government and the pharmaceutical industry have ended without an agreement on changes ...
Posted by Michael Wonder on 29 Aug 2025
Public Summary Documents – May 2025 PBAC meeting
29 August 2025 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2025 PBAC ...
Posted by Michael Wonder on 29 Aug 2025
Agenda for the September 2025 PBAC intracycle meeting
29 August 2025 - The agenda for the September 2025 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 25 Aug 2025
Bewildering PBAC decision a missed opportunity to ensure Australian cancer patients not left behind
23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the ...
Posted by Michael Wonder on 25 Aug 2025
Recommendations made the PBAC – July 2025
22 August 2025 - The recommendations from the July 2025 PBAC meeting are now available. ...
Posted by Michael Wonder on 25 Aug 2025
Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer
23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...
Posted by Michael Wonder on 25 Aug 2025
Injectable form of Ocrevus for relapsing remitting multiple sclerosis recommended for PBS listing
22 August 2025 - This new form of ocrelizumab is given as an injection under the skin (subcutaneously), takes a much ...
Posted by Michael Wonder on 24 Aug 2025
New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year
23 August 2025 - New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k/year. ...
Posted by Michael Wonder on 22 Aug 2025
DoH publishes revised agenda for November 2025 PBAC meeting (version 2)
20 August 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting. ...
Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to ...
Posted by Michael Wonder on 22 Aug 2025
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
21 August 2025 - NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 14 Aug 2025
Final decision on cerliponase alfa for Batten disease treatment confirmed
14 August 2025 - In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (Brineura; BioMarin) ...
Posted by Michael Wonder on 12 Aug 2025
New and expanded PBS listings for endometrial cancer, neuroblastoma, Parkinson's disease and melanoma
11 August 2025 - Australians with Parkinson’s disease, neuroblastoma, endometrial cancer, cystic fibrosis and melanoma will have access to new ...
Posted by Michael Wonder on 11 Aug 2025
SMC - August 2025 decisions
11 August 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...